SCHEMBL2894259

SCHEMBL2894259

CSc1ccc(C)nc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21321543 0.78
SCHEMBL3602693 0.75 ALDH1A1 (0.34)
SCHEMBL4030382 0.75 MEN1 (0.40)
SCHEMBL10297522 0.75 MEN1 (0.42)
SCHEMBL12148707 0.75 MEN1 (0.36)
SCHEMBL10049917 0.75 MEN1 (0.42)
SCHEMBL5644739 0.73
SCHEMBL8441489 0.73
SCHEMBL838791 0.73
SCHEMBL5700222 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250179022-A1 COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF SHANGHAI ZHIGEN PHARMACEUTICAL & TECHNOLOGY CO. LTD. (CN) 2025-06-05 US disclosed
CN-119317622-A Compounds useful as TYK2 inhibitors, preparation method and application thereof in medicine 上海致根医药科技有限公司 2025-01-14 CN disclosed
EP-4488268-A1 COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF Shanghai Zhigen Pharmaceutical & Technology Co. Ltd. (CN) 2025-01-08 EP disclosed
US-12018045-B2 17-beta-hydroxywithanolides and use thereof in treating cancer THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-06-25 US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 US disclosed
US-20230295108-A1 ARYLTETRAHYDROPYRIDINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF NIHON NOHYAKU CO., LTD. (JP) 2023-09-21 US disclosed
US-20230295108-A1 ARYLTETRAHYDROPYRIDINE DERIVATIVE OR SALT THEREOF, INSECTICIDAL AGENT CONTAINING THE COMPOUND, AND METHOD OF USE THEREOF NIHON NOHYAKU CO., LTD. (JP) 2023-09-21 US disclosed
WO-2023165574-A1 COMPOUND USED AS TYK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF 上海致根医药科技有限公司 2023-09-07 WO disclosed
CN-116693449-A Compounds useful as TYK2 inhibitors, preparation method and application thereof in medicine 上海致根医药科技有限公司 2023-09-05 CN disclosed
US-20230265098-A1 ALKYNE QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN INC. 2023-08-24 US disclosed
EP-2116535-A1 GLUCOKINASE-ACTIVATING SUBSTANCE Kyorin Pharmaceutical Co., Ltd. (JP) 2009-11-11 EP disclosed
WO-2009133687-A1 CYCLOPENTYLACRYLIC ACID AMIDE DERIVATIVE 杏林製薬株式会社 (JP) 2009-11-05 WO disclosed
WO-2009051715-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2009-04-23 WO disclosed
US-7183296-B2 Anti-HIV pyrazole derivatives ROCHE PALO ALTO LLC (US) 2007-02-27 US disclosed
US-7169930-B2 Analogs of epothilone THE SCRIPPS RESEARCH INSTITUTE (US) 2007-01-30 US disclosed
US-20040192752-A1 Anti-HIV pyrazole derivatives DYMOCK BRIAN WILLIAM (GB) 2004-09-30 US disclosed
US-6699887-B2 ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A PYRRAZOLE SULFIDE OR ETHER COMPOUND TO TREAT THE HUMAN IMMUNODEFICIENCY VIRUS INFECTION HOFFMANN-LA ROCHE INC. 2004-03-02 US disclosed
EP-1326843-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. Hoffmann-La Roche AG (CH) 2003-07-16 EP disclosed
US-20030018197-A1 Anti-HIV pyrazole derivatives HOFFMANN-LA ROCHE INC. 2003-01-23 US disclosed
WO-2002030907-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES F. HOFFMANN-LA ROCHE AG (CH) 2002-04-18 WO disclosed